DBV Technologies downgraded by Societe Generale
$DBVT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Societe Generale downgraded DBV Technologies from Hold to Sell
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/29/2025 | $7.25 | Sell | Goldman |
| 1/4/2023 | Hold → Buy | Societe Generale | |
| 12/16/2022 | Neutral → Sell | Goldman | |
| 5/10/2022 | $6.00 → $1.50 | Buy → Neutral | Goldman |
| 12/21/2021 | $8.00 → $5.00 | Market Outperform | JMP Securities |
| 12/21/2021 | $14.00 → $10.00 | Buy | HC Wainwright & Co. |
| 9/14/2021 | Hold → Buy | Societe Generale |
8-K - DBV Technologies S.A. (0001613780) (Filer)
S-8 - DBV Technologies S.A. (0001613780) (Filer)
8-K - DBV Technologies S.A. (0001613780) (Filer)
Goldman resumed coverage of DBV Technologies with a rating of Sell and set a new price target of $7.25
Societe Generale upgraded DBV Technologies from Hold to Buy
Goldman downgraded DBV Technologies from Neutral to Sell
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patc
Châtillon, France, January 8th, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12No treatment-related anaphylaxis or serious treatment-related Treatment-Emergent Adverse Events (TEAEs) occurred in year three of EPITOPE OLE DBV also announced daily patch wear time data from EPITOPE that is supportive of the Company's proposed labeling approach shared with FD
Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025Viaskin Peanut patch BLA submission for the Toddlers indication anticipated for 2H 2026 FDA confirmed criteria for post-marketing confirmatory study in toddlers 1 – 3 years-oldCompany to host investor webcast today at 5:00pm ET DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, tod
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
4 - DBV Technologies S.A. (0001613780) (Issuer)
3 - DBV Technologies S.A. (0001613780) (Issuer)
3 - DBV Technologies S.A. (0001613780) (Issuer)
Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patc
Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United Kingdom. DBV will present two posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the reduced rate of reactions from accidental peanut consumption (APC) with the VIASKIN® peanut patch versus placebo in Year 2 of the Company's EPITOPE open-label extension (OLE) trial, as w
Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company (the "Company"), held its Combined General Meeting (the "General Meeting"). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company's shareholders approved all resolutions submitted by the Board of Directors. The resolutions and the voting results are posted on the Investors/Annual General Meetings section of the Company's website: https://dbv-technologies.com/events/2025-annual-general-meeting/. About DBV TechnologiesDB
Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024. Recent
Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023. An experienced financial and operations executive, Virginie will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of the Executive Committee. "I am pleased to welcome Virginie to the DBV Executive Committee to lead our global financial organization," said Daniel Tassé, Chief Executive Officer, DBV Tech
Montrouge, France, October 3, 2022 DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced that Mr. Timothy E. Morris, Independent Director and Member of the Audit Committee of the Board of Directors ("the Board"), was appointed as Chairperson of the Board's Audit Committee in replacement of Ms. Viviane Monges, who resigned from the Board effective October 3, 2022. DBV also announced the Board's provisional appointment of Ms. Daniele Guyot-Caparros as Independent Director to fill Ms. Monges' vacancy, effective October